Acer therapeutics and relief therapeutics announce receipt of notice of allowance of us patent application covering a kit comprising phenylbutyrate and sodium benzoate

Notice of allowance covering these claims further strengthens acer-001 proprietary position in us; patent expected to be issued in q4 2022 and expire in 2038 notice of allowance covering these claims further strengthens acer-001 proprietary position in us; patent expected to be issued in q4 2022 and expire in 2038
ACER Ratings Summary
ACER Quant Ranking